ADVERTISEMENT
Inflammatory Cytokine Changes in Patients With Psoriatic Arthritis Taking TNFα and IL-17A Inhibitors
According to a study published in International Journal of Molecular Sciences, differing changes in cytokine levels highlight the need to improve the understanding of the different immune response mechanisms in patients with psoriatic arthritis (PsA).
Researchers investigated changes in biomarker levels among responders and nonresponders to tumor necrosis factor alpha inhibitor (TNFi) and IL-17A inhibitor (IL-17Ai) treatments in patients with PsA over a 4-month period. A cohort of 68 patients with PsA initiating TNFi, IL-17Ai, or methotrexate treatment was followed, with blood plasma and clinical outcomes assessed at treatment initiation and after 4 months. Using a multiplex immunoassay, 54 biomarkers were evaluated.
Results showed a significant decrease in pro-inflammatory cytokine IL-6 and an increase in anti-inflammatory IL-10 levels among TNFi responders. In contrast, IL-17Ai responders and nonresponders exhibited a significant increase in IL-17A levels. These findings underscored differing changes in cytokine levels between treatment responders and nonresponders, suggesting varied immune response mechanisms contributing to treatment outcomes in patients with PsA.
The study's findings shed light on the complex interplay between cytokine modulation and treatment response in PsA, emphasizing the importance of understanding individual patient responses to different therapies. By elucidating these immune response mechanisms, clinicians can potentially tailor treatment strategies more effectively to optimize outcomes for patients with PsA. Further research in this area is warranted to explore the underlying mechanisms driving treatment response variability and to inform personalized treatment approaches in PsA management.
Reference
Skougaard M, Skougaard MF, Ditlev SB, Kristensen LE. Changes in inflammatory cytokines in responders and non-responders to TNFα inhibitor and IL-17A inhibitor: a study examining psoriatic arthritis patients. Int J Mol Sci. 2024;25(5):3002. doi:10.3390/ijms25053002
© 2024 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of The Dermatologist or HMP Global, their employees, and affiliates.
